eletriptan (relpax) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Eletriptan (eletriptan hydrobromide, trade name Relpax) is a selective 5-hydroxytryptamine (5-HT1B/1D) serotonin receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, and has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors. The therapeutic activity of eletriptan for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Eletriptan (Relpax) has been approved for use in the acute treatment of migraine in 51 countries and has been introduced in 17 countries including Mexico, Italy, France and Japan.   NCATS

Chemistry

  • SMILES: CN1CCC[C@@H]1Cc2c[nH]c3ccc(CCS(=O)(=O)c4ccccc4)cc23
  • InChIKey: PWVXXGRKLHYWKM-LJQANCHMSA-N
  • Mol. Mass: 382.53
  • ALogP: 3.82
  • ChEMBL Molecules:
    eletriptan  
    eletriptan hydrobromide  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.1033 - $100.0700

Australia

$2.9364
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole hydrobromide | eletriptan | eletriptan hydrobromide | eletriptanum | (r)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole | (r)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole monohydrobromide | relpax | uk-116044 | uk-116,044 | uk 116044-04 | uk-11604404 | uk-116,044-04 | uk-116044-04 | uk-116044-04 [as hydrobromide) | uk 166044 | uk 166,044 | uk-166044 | uk-166,044

Organizations (19)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (13)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (2)


 

Cluster Headache

Migraine Disorders (approved 2002)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Healthy Volunteers (Phase 1)

Migraine Disorders ()

Migraine with Aura (Phase 3)

Migraine without Aura (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue